Carl Byrnes
Stock Analyst at Northland Capital Markets
(2.31)
# 2,593
Out of 4,752 analysts
23
Total ratings
56.25%
Success rate
8.03%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $26.33 | +17.74% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $5.35 | +133.64% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $10.60 | +17.92% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $1.87 | +220.86% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.59 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $2 → $1.25 | $0.55 | +126.24% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $8 | $0.47 | +1,614.53% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $15.72 | +408.91% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $8.55 | +169.01% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $1.88 | +1,176.60% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $1.59 | +125,686.16% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.81 | - | 1 | Sep 27, 2017 |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $26.33
Upside: +17.74%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $5.35
Upside: +133.64%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $10.60
Upside: +17.92%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $1.87
Upside: +220.86%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.59
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $2 → $1.25
Current: $0.55
Upside: +126.24%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $8
Current: $0.47
Upside: +1,614.53%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $15.72
Upside: +408.91%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $8.55
Upside: +169.01%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $1.88
Upside: +1,176.60%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $1.59
Upside: +125,686.16%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.81
Upside: -